# BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

> **NCT06441890** · PHASE2 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 28 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT06441890
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441890, "BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06441890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*